← Leaderboards
Anthony Rongvaux
University Of Washington
$4,527,674
Attributed
$5,925,380
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,925,380 · 4
By mechanism
R01$4,996,126 · 2
R21$929,254 · 2
Top collaborators
- Daniel B Stetson4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Andrew Atwell Oberst$17,614,781
- Mehul Shamal Suthar$8,747,894
- Alan A Aderem$59,360,862
- Daniel B Stetson$16,337,119
- Edward A Clark$26,060,534
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneCellsMouse ModelIn VivoIn VitroHumanized MouseBiologyTumorMelanomaMelanoma CellMolecularCell TypeNeoplastic CellCell LineImmune SystemInnovationPublic HealthComplexMalignant NeoplasmsSolid NeoplasmTumor MicroenvironmentCessation Of LifeOutcome PredictionMacrophage
Grant awards (14)
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy$712,871
R01 · FY2025 · CA
In vivo innate immune sensing of HIV-1 infection$213,502
R21 · FY2025 · AI · contact PI
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy$681,404
R01 · FY2024 · CA
In vivo innate immune sensing of HIV-1 infection$231,752
R21 · FY2024 · AI · contact PI
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy$682,539
R01 · FY2023 · CA
Targeting macrophages in metastatic cancer$415,679
R01 · FY2023 · CA · contact PI
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy$718,598
R01 · FY2022 · CA
Targeting macrophages in metastatic cancer$359,162
R01 · FY2022 · CA · contact PI
Targeting macrophages in metastatic cancer$65,000
R01 · FY2022 · CA · contact PI
Targeting macrophages in metastatic cancer$455,525
R01 · FY2021 · CA · contact PI
Targeting macrophages in metastatic cancer$459,802
R01 · FY2020 · CA · contact PI
Regulation of Natural Killer Cells by Caspases$264,000
R21 · FY2020 · AI · contact PI
Targeting macrophages in metastatic cancer$445,546
R01 · FY2019 · CA · contact PI
Regulation of Natural Killer Cells by Caspases$220,000
R21 · FY2019 · AI · contact PI